DelveInsight’s “Neuropathic Pain Market Insights, Epidemiology, and Market Forecast-2032“ report delivers an in-depth understanding of the Neuropathic Pain, historical and forecasted epidemiology as well as the Neuropathic Pain market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Neuropathic Pain market report provides current treatment practices, emerging drugs, Neuropathic Pain market share of the individual therapies, and current and forecasted Neuropathic Pain market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Neuropathic Pain treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Neuropathic Pain market.
Some of the key facts of the Neuropathic Pain Market Report:
- As per Cancer Research UK, melanoma is the fifth most common cancer in the UK. There are around 16,200 new melanoma skin cancer cases in the UK every year. Incidence rates for melanoma skin cancer are projected to rise by 7% in the UK between 2014 and 2035, to 32 cases per 100,000 people by 2035.
Key benefits of the Neuropathic Pain report:
- The report covers the descriptive overview of Melanoma, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
- Comprehensive insight has been provided into the Melanoma epidemiology and treatment in the 7MM
- Additionally, an all-inclusive account of both the current and emerging therapies for Melanoma is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
- A detailed review of the Melanoma market; historical and forecasted is included in the report, covering drug outreach in the 7MM
- The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Melanoma market
Got queries? Click here to know more about the Neuropathic Pain Market Landscape
Neuropathic Pain Overview
As per the American Skin Association, Melanoma is a life threatening Metastatic tumor that originates in cells called melanocytes, which are pigment-producing cells. The majority of Melanomas are black or brown. However, some Melanomas are skin-colored, pink, red, purple, blue or white. Melanoma begins on the skin where it is easy to see and treat. However, it can grow into the skin, reaching the blood vessels and lymphatics, and can spread within the body to various organs when it can be fatal. If it is recognized and treated early, chances of recovery are very good. But if it is not found early, it can grow deeper into the skin, and spread to other parts of the body. Once Melanoma spreads beyond the skin to other parts of the body, it becomes hard to treat and can be fatal.
Early detection of melanoma is a key point for melanoma therapy. There are various diagnosis options, such as assessing biopsy, imaging techniques, and biomarkers (i.e., several proteins, polymorphism, and liquid biopsy). Among the various biomarkers, assessing circulating tumor cells, cell‐free DNAs, cell‐free RNAs, and microRNAs (miRNAs) have emerged as powerful diagnostic tools for melanoma patients. There are several risk factors that increases the risk of melanoma which includes UV rays ( being the most crucial one), moles , and family history of melanoma.The stage of a cancer at diagnosis will indicate how far it has already spread and what kind of treatment will be suitable. One method of assigning a stage to Melanoma describes the cancer in five stages, from 0 to 4. The more advanced a cancer is, the harder it is to treat and the worse the outlook becomes.
Neuropathic Pain Epidemiological Insights:
Melanoma of the skin represents 5.6% of all new cancer cases in the U.S., with the rate of new cases of melanoma of the skin was 22.7 per 100,000 per year. The death rate was 2.3 per 100,000. These rates are age-adjusted and based on 2013–2017 cases and 2014–2018 deaths.
As per the National Cancer Institute, in 2020, an estimated 6,850 persons died from melanoma in the United States. For melanoma of the skin, death rates are higher among the middle-aged and elderly. More than 65% of the deaths due to Melanoma is between the age group of 55 to 85 years.
According to Cancer.Net, if melanoma has spread to other, distant parts of the body, the survival rate is lower, about 27%. Approximately 4% of cases are diagnosed at this stage.
According to the SEER estimates, 106,110 new cases of Melanoma were observed in 2021. More than half of the new cases occurs in patients with 60+ years of age.
Neuropathic Pain Epidemiological Segmentation
- Neuropathic Pain Incident cases
- Neuropathic Pain stage-specific cases
- Neuropathic PainType-specific cases
- Neuropathic Pain Mutation-specific (BRAF, MEK) Cases
Neuropathic Market Pain Outlook
The Neuropathic Pain market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Neuropathic Pain market trends by analyzing the impact of current Neuropathic Pain therapies on the market, unmet needs, drivers and barriers, and demand for better technology.
This segment gives a thorough detail of Neuropathic Pain market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Neuropathic Pain market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the Neuropathic Pain market in 7MM is expected to witness a major change in the study period 2019-2032.
Learn more by requesting for sample @Neuropathic Pain Landscape
Neuropathic Pain Key Companies
- WEX Pharmaceuticals Inc
- Lexicon Pharmaceuticals Inc
- Bayer
- And others.
Neuropathic PainTherapies
- Halneuron
- LX9211
- BAY2395840
- And others.
Table of Contents
- Key Insights
- Report Introduction
- Executive Summary of Neuropathic Pain
- Disease Background and Overview
- Epidemiology and patient population
- The United States
- EU 5
- Neuropathic Pain Emerging Therapies
- Neuropathic Pain Outlook
- Market Access and Reimbursement of Therapies
- Appendix
- Melanoma Report Methodology
- DelveInsight Capabilities
- Disclaimer
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
